\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesShare your good practice and showcase how you improve access for companies to use Research and Technology Infrastructures.
Policy context
The European Strategy on Research and Technology Infrastructures calls for improving the access to Research and Technology infrastructures for industrial users. To accelerate and support this, the European Commission is launching an outreach campaign to increase the visibility of infrastructure services, facilitate peer-learning and provide networking opportunities.
Call for good practices: Share what works
To kick-off the outreach campaign, the European Commission invites infrastructure hosts and operators to share examples of good practices that improve access to research and technology infrastructures for industrial actors, especially SMEs, startups or scaleups.
Next steps in the campaign
The practices will be collected in an open repository for peer learning purposes, and will feed into outreach activities, such as a series of online seminars. The Commission will also host physical events to facilitate networking.
More information about this initiative, including the submission guidelines (PDF) and form to submit your best practice, is available in the announcement on the European Commission DG R&I webpage.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Agro-Food, Environment Missions
The FOREST Partnership has opened a call for experts read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
